Clinical Trial

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-23; most recent amendment 2025-08-13.
Status change: Not Yet Recruiting → Recruiting 2022-09-01
Trial Details
NCT Number NCT05394103
Lead Sponsor Qurient Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced Cancer, Metastatic Cancer
Enrollment 130 participants
Start Date 2022-08-30
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-17